NASDAQ: ALMS
#Biotechnology
NASDAQ: APLS; FDA approval of SYFOVRE (pegcetacoplan) for geographic atrophy (Feb 17, 2023).
#Ophthalmology / complement therapeutics
Acquired by Johnson & Johnson (press link provided).
#Pharmaceuticals / oncology
Received FDA Fast Track designation for AB-101 (Jan 31, 2023); established U.S. research and manufacturing facility (Aug 12, 2021).
#Cell therapy / oncology (NK cell therapies)
Launched with $60M Series A; press link provided.
#Biotechnology / biologics
Presented pan-amyloid diagnostic data at ACC (Apr 1, 2025).
#Diagnostics / amyloid
NASDAQ: AUPH
#Immunology / rare disease
#Biotechnology / ophthalmology
#Digital therapeutics / biotech
Acquired by Regeneron (press link provided).
#Oncology
Acquired by AstraZeneca (press link provided).
#Cardiorenal / therapeutics
NASDAQ: ELEV; priced IPO (June 24, 2021).
#Oncology
NASDAQ: HRMY; reported Q1 2025 financial results (May 6, 2025); commercial product WAKIX for narcolepsy.
#Rare neurological diseases / neurology
#Research services / histology
Acquired by Lyell Immunopharma (press link provided).
#Cell therapy / immunology
NASDAQ: IMPL; commercial product Trudhesa (dihydroergotamine nasal spray); announced strategic reprioritization (Feb 22, 2023).
#Neurology / migraine therapeutics
Acquired by Teva Pharmaceuticals (press link provided).
#Neurology / migraine
NASDAQ: LYEL
#Cell therapy / immuno-oncology
Published Phase 2a MAR001 data in The Lancet (May 16, 2025).
#Cardiovascular / therapeutics
Announced agreement with Daewoong Pharmaceutical to develop fexuprazan for acid-related GI disorders in U.S. (June 8, 2021).
#Gastrointestinal / therapeutics
#Cardiometabolic / therapeutics
SEFA platform; ICONA Phase 2b (icosabutate) top-line expected Q1 2023; multiple SEFA programs advancing.
#NASH / metabolic diseases
#Biotechnology / therapeutics
Nasdaq: PHVS; presented Phase 2 RAPIDe-1 data for PHVS416 (Feb 24, 2023); Jun 2, 2025 portfolio news on deucrictibant.
#Rare disease / HAE (hereditary angioedema)
NASDAQ: DTIL
#Genome editing / biotechnology
Secured $108M Series C financing (June 15, 2021).
#Radiopharmaceuticals / oncology
Acquired by Genentech/Roche (press link provided).
#Oncology
Appointed Kevin N. Heller, M.D., as CMO (Jan 24, 2023).
#Oncology / immunotherapy
Acquired by Bristol Myers Squibb (press link provided).
#Oncology / precision medicine
NASDAQ: VTYX; pipeline includes TYK2, S1P1R, and NLRP3 programs; investor R&D day Jan 2023.
#Inflammation / immunology (oral small molecules)